A significant development in the fight against dengue fever has emerged from KPJ Damansara Specialist Hospital in Petaling Jaya, Selangor. The facility has introduced Malaysia’s first dengue vaccine, known as Qdenga. Developed by the Japanese pharmaceutical company Takeda, this live-attenuated tetravalent vaccine aims to provide a comprehensive defence against all four serotypes of the dengue virus.

The vaccination package at KPJ Damansara includes two doses, administered three months apart, and is priced at RM400. Dr Musa Mohd Nordin, a consultant paediatrician, emphasised the importance of this vaccine during the launch event titled “Merdeka from Dengue Deaths” on August 24. He stated that individuals aged four and older should seriously consider vaccination, as the vaccine has demonstrated an 84% reduction in the risk of severe dengue and a significant decrease in hospitalisation rates.

Dr Musa reassured the public regarding the safety of the vaccine, noting, “There have been no major adverse effects associated with the dengue vaccine.” This statement is critical, given the rising concerns surrounding vaccine safety in general. The confidence in Qdenga comes at a crucial time as Malaysia grapples with a rising number of dengue cases and fatalities.

The Ministry of Health (MOH) recently reported concerning statistics, revealing a cumulative total of 92,827 dengue cases for the 33rd epidemiological week of 2024, which spans from August 11 to August 17. This figure represents a staggering 22 per cent increase compared to the 75,928 cases recorded within the same timeframe of the previous year. Furthermore, 83 deaths linked to complications from dengue fever have been reported this year, reflecting a startling 54 per cent rise from the 54 deaths reported during this period in 2023.

Dr Musa pointed out that dengue fever poses a significant economic burden on Malaysia. The limitations of vector control measures have become evident; despite various efforts to reduce mosquito populations, effective transmission reduction has not been fully realised. “Vector control has achieved only limited success,” he remarked. He advocates for incorporating vaccination into broader strategies for dengue prevention and management.

Financially, the cost implications of dengue are staggering. In 2019 alone, the economic burden of dengue illness was estimated at RM196 million. This figure was compounded by RM260 million spent on dengue prevention and control measures in 2018, bringing the total annual expenditure related to dengue to RM456 million. These figures highlight not only the health implications but also the fiscal challenges posed by this endemic disease.

Research conducted in 2018 indicated that a substantial portion of hospitalised dengue patients endure prolonged hospital stays. According to Dr Musa, half of those hospitalised for dengue required more than three days of care. This extended duration exacerbates healthcare costs and resource allocation issues within hospitals already strained by high patient volumes.

Currently, there is no definitive curative treatment for dengue fever. The management of the disease primarily focuses on supportive care. Without antiviral treatments available, healthcare providers often face challenges in addressing severe cases effectively. Moreover, individuals who contract dengue for a second time are at an increased risk of developing severe forms of the disease, which can be fatal—a reality that amplifies the urgency for preventive strategies like vaccination.

Nurul Izzah Anwar, chairwoman of the Social & Economic Research Initiative (SERI) and former Lembah Pantai MP, during the event, highlighted the persistent struggle against dengue within Malaysia. She remarked on the government’s extensive efforts to combat this public health issue through mosquito control programmes and community engagement initiatives aimed at eliminating breeding sites. Despite these initiatives, Malaysia continues to face a high incidence of dengue fever cases.

The urgent need for effective solutions is underscored by the alarming statistics released by MOH. With a relentless rise in dengue cases and deaths, public health officials are under pressure to implement strategies that can alleviate this growing crisis. Vaccines like Qdenga represent a pivotal step forward in providing protection against this public health threat.

As Malaysia navigates these challenges, collaboration between healthcare professionals, researchers, and policymakers will be crucial in formulating comprehensive approaches to tackle dengue effectively. The introduction of Qdenga is a promising development that could reshape how Malaysia confronts this persistent health challenge.

In light of these developments, it is clear that while vector control measures remain an essential part of tackling dengue, integrating vaccination into public health strategies may offer a more effective pathway towards reducing both incidence and mortality associated with this disease.